Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

men. The primary endpoint of the study is PFS. This global study, conducted by Janssen outside the US, is recruiting and Janssen plans to enroll 280 patients.
  • SHINE (MCL3002): Phase III study of ibrutinib in combination with bendamustine and rituximab in elderly patients with newly diagnosed MCL. This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in patients 65 years or older with newly diagnosed MCL. The primary endpoint of the study is PFS. This global study, conducted by Janssen, is recruiting and Janssen plans to enroll 520 patients.
  • MCL4001: A multicenter, open label Expanded Access Program (EAP) for ibrutinib as a monotherapy in relapsed/refractory (R/R) MCL patients has been initiated in the US by Janssen. EAPs are clinical studies allowed under certain circumstances by the FDA. They are designed to provide a mechanism for access to an investigational drug to treat patients with a serious or immediately life-threatening diseases or conditions until the time of an anticipated U.S. marketing approval. Further information about this program can be found on www.clinicaltrials.gov.
  • DLBCL

  • PCYC-1106: Phase II study of ibrutinib in patients with relapsed or refractory DLBCL. This trial is a multicenter, open-label study designed to assess the activity of ibrutinib in two genetically distinct subtypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center B-cell (GCB) subtype. This trial is active in several US sites and Pharmacyclics has enrolled 70 patients with updated results most recently published at EHA in June 2013. In July a new cohort with ibrutinib dosed at 840mg in patients with non-GCB subtype DLBCL was initiated. This cohort will increase the enrollment target for this study to 125 patients.
  • DBL1002: Phase Ib dose escalating stu
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
    (Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
    (Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
    Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
    ... VIEW, Calif., Feb. 23, 2011 Omnicell, Inc ... of medication management systems to healthcare facilities, today announced ... 100 healthcare executives were polled to identify trends in ... purchasing decisions. The survey found that the majority of ...
    ... Biomatrica, Inc., a leader in room temperature biostability ... In-Q-Tel (IQT). IQT is the independent, strategic investment ... the mission of the U.S. Intelligence Community. ... has pioneered recent innovations in ambient storage of ...
    Cached Medicine Technology:75 Percent of Hospital IT Leaders View Interoperability Between Vendor Systems as Critical to Operational Effectiveness in Healthcare Settings 2Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
    (Date:3/2/2015)... March 02, 2015 Secura Consultants ... relationship with First Protective Insurance Group of Birmingham, ... allow First Protective affiliated advisors to access the ... that Secura Consultants delivers. , Secura ... leader in the design and implementation of insured ...
    (Date:3/1/2015)... March 01, 2015 Women’s Excellence is ... Obstetric terms on their website. There are over 75 ... the time. , “This gives our patients a better ... medical terminology that they may not understand. With this resource, ... is mobile optimized) and find terms and phrases that they may ...
    (Date:3/1/2015)... NC (PRWEB) March 01, 2015 Researchers ... reason that so many sheet metal workers contract malignant ... this new report on its website. Click here ... Center for Construction Research and Training monitored 17,345 sheet ... a disproportionate number of them died of mesothelioma ...
    (Date:3/1/2015)... 01, 2015 Indiana Fiber Network, ... Provider, announces NewWays Networking, LLC (NewWays) selected IFN ... with IFN, NewWays is well positioned to scale ... for Internet bandwidth in rural parts of Indiana,” ... to Cory Childs IFN Enterprise Sales Manager, IFN ...
    (Date:3/1/2015)... Vancouver, WA (PRWEB) February 28, 2015 CrossFit ... This spring they are offering a special discount to new ... who sign up for a three month contract will receive ... each month individually would cost members $440. The three ... $88 per month, and then the fourth month comes in ...
    Breaking Medicine News(10 mins):Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2
    ... was no better than placebo, study finds , , MONDAY, ... (Trileptal) does not seem to prevent migraines, as once ... than 28 million Americans, and certain epilepsy drugs have ... headaches. For this reason, many assumed that oxcarbazepine would ...
    ... at Annual Meeting of the American Academy of ... ... NeoStrata today released new,clinical data that demonstrates significant benefits in combining,microdermabrasion ... products in improving the appearance,and texture of facial skin. The data ...
    ... for donations is spiraling for older couples wanting to start ... ... Radical shifts in parenting,trends have fertility experts at Reproductive Endocrinology Associates of,Charlotte ... in 2008 -- including new outreach through the Internet --,in efforts to ...
    ... the day that we,celebrate love approaches, many people with memory-impaired ... sustain a loving,relationship with someone who no longer knows who ... a new understanding of love itself., "It,s important to ... matters most is doing things that make him or her ...
    ... Show All 89 Inspected Pennsylvania Facilities Meet Federal,Standards, ... of,Environmental Protection reported today that all of the ... are operating within,the guidelines set forth by the ... each of Pennsylvania,s approximately 400 certified,mammography facilities annually ...
    ... saturate TV, radio, and print with anti-Meth ... ... The Illinois Meth Project,today launched a campaign to prevent first-time methamphetamine ... a research-based prevention program that educates people,about the dangers of Meth ...
    Cached Medicine News:Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin 2Health News:Charlotte IVF Experts Issue Urgent Call for Egg Donors, Eye New Recruiting Tools 2Health News:Loving the Memory-Impaired: A New Perspective on Valentine's Day 2Health News:Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 2Health News:Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 3Health News:Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 4Health News:Illinois Meth Project Launches Large-Scale Meth Prevention Campaign 2Health News:Illinois Meth Project Launches Large-Scale Meth Prevention Campaign 3Health News:Illinois Meth Project Launches Large-Scale Meth Prevention Campaign 4
    The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
    ... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
    Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
    ... we believe that the trocar should be ... instrument precision and speeding the process. So ... trocar that meets the needs of the ... Xcel - The only trocar that affords ...
    Medicine Products: